Is It Time to Dump Your Shares of Eli Lilly?

Eli Lilly has surged to market leadership in GLP-1 injectable weight-loss drugs but now trades at a rich ~53x P/E, prompting suggestions to take profits as competitors advance. Novo Nordisk, the original GLP-1 developer, is set to launch an oral pill in early 2026 and trades at ~15x P/E (roughly half its five-year average), while Pfizer (P/E just under 10) has added GLP-1 assets via acquisition and distribution deals and is positioned as a value turnaround candidate. The note highlights that patent protection alone won’t secure market share if competitors deliver more attractive formulations, implying potential material shifts in market share and valuations across these large-cap pharma names.

Analysis

Market structure: Lilly (LLY) currently captures the bulk of GLP-1 revenues; Novo (NVO) is a clear potential winner if its oral GLP-1 gains share after projected early‑2026 launch, and Pfizer (PFE) is a value recovery candidate via M&A/pipeline deals. Expect pricing pressure from payers as headline demand (millions of patients) meets supplier ramp constraints; payers and CMS are the pivotal marginal buyer that can cap list prices and net margins.

Risk assessment: Key tail risks are an FDA safety signal on chronic GLP‑1 use, aggressive payer coverage limits within 6–12 months, or manufacturing setbacks for oral peptides — each could wipe 20–40% off forward revenue scenarios. Short‑term (days–weeks) reactions will be sentiment driven around earnings/approval news; medium (3–12 months) depends on coverage decisions and launch execution; long‑term (2–5 years) hinges on patent cliffs and class fragmentation.

Trade implications: Favor dollar‑neutral relative plays: long NVO vs short LLY into early‑2026 (expect 15–30% relative re‑rating if pill gains traction). Use options: sell covered calls on existing LLY or buy 12–18 month PFE LEAPS (10–20% OTM) as asymmetric upside; position sizes 2–5% portfolio with 12–24 month horizon and 12–15% hard stops.

Contrarian view: The market prices Lilly for perfection (P/E ~53) and may underprice Pfizer’s optionality (P/E ~10) and Novo’s pickup if oral adoption is strong. Historical parallels (first‑mover biologic losing to superior delivery) argue the stock re‑ratings can be rapid; unintended consequence is payer caps that compress margins for all players, not only winners.

Key Decisions for Investors

• Trim LLY exposure by 25–40% within 1–4 weeks to lock gains (LLY P/E ~53). Deploy proceeds: 60% into NVO and 40% into PFE.
• Establish a 2–3% long position in NVO now and add to reach 4–6% by Jan 2026 conditional on positive regulatory/commercial milestones; target +20–30% by Q4 2026, stop loss 15% below entry.
• Buy a 3–5% portfolio-sized long in PFE via Jan‑2027 LEAPS ~10–20% OTM (or a call spread) to capture turnaround optionality; target +40%+ if pipeline/partnership catalysts materialize, stop loss 20%.
• Run a dollar‑neutral pair: long NVO / short LLY sized 1–2% each, horizon 6–12 months, close or rebalance on Novo commercial traction (measured by >5% GLP‑1 market share gains reported in quarterly sales) or if payer reimbursement guidance tightens.